公开(公告)号：US20220178932A1

公开(公告)日：2022-06-09

申请号：US17605327

申请日：2020-04-15

Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH ,  OSAKA UNIVERSITY ,  TOSOH CORPORATION

Inventor： Koji UEDA ,  Naomi OHNISHI ,  Kazutake TSUJIKAWA ,  Norio NONOMURA ,  Motohide UEMURA ,  Kentaro JINGUSHI ,  Norihisa OHTAKE ,  Yasutoshi KAWAI

IPC: G01N33/574 ,  G01N33/535

Abstract: An object of the invention is to provide a method for detecting cancer in a simple and highly accurate manner, and a reagent that can be used in the method. A method for detecting cancer (excluding renal cell cancer), which comprises measuring the level of Azurocidin (AZU1) in a sample, in which it is determined that cancer is detected when a measured value exceeds a preset reference value. The cancer is preferably selected from the group consisting of stomach cancer, breast cancer, colorectal cancer, and lung cancer. A reagent containing an antibody that specifically recognizes AZU1 is used in detecting cancer (excluding renal cell cancer).

公开(公告)号：US20230053846A1

公开(公告)日：2023-02-23

申请号：US17778593

申请日：2020-11-13

Applicant: OSAKA UNIVERSITY ,  TOSOH CORPORATION

Inventor： Motohide UEMURA ,  Norio NONOMURA ,  Takeshi UJIKE ,  Shohei MYOBA ,  Norihisa OHTAKE

IPC: G01N33/574 ,  C07K16/22

Abstract: A problem to be addressed by the present invention is to provide: a method for detecting bone metastasis of cancer (excluding castration resistant prostate cancer) in a simple and highly accurate manner; and a reagent that can be used in the method. Bone metastasis of cancer (excluding castration resistant prostate cancer) is detected by measuring an intact growth and differentiation factor 15 (GDF15) propeptide level, a GDF15 propeptide fragment level, and the total of an intact GDF15 propeptide level and a GDF15 propeptide fragment level in a sample. The above described method for detecting bone metastasis of cancer includes a method for detecting bone metastasis of prostate cancer other than castration resistant prostate cancer, renal cancer, lung cancer, breast cancer, thyroid cancer, pancreatic cancer, bladder cancer, colon cancer, melanoma, myeloma, or lymphoma. Further, the reagent for detecting bone metastasis of cancer (excluding castration resistant prostate cancer) includes an antibody that specifically recognizes GDF15 propeptide.